1. Home
  2. FTRE vs NVCR Comparison

FTRE vs NVCR Comparison

Compare FTRE & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

HOLD

Current Price

$10.39

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo NovoCure Limited

NVCR

NovoCure Limited

HOLD

Current Price

$13.47

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTRE
NVCR
Founded
1996
2000
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Medical Specialities
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
2023
2015

Fundamental Metrics

Financial Performance
Metric
FTRE
NVCR
Price
$10.39
$13.47
Analyst Decision
Buy
Buy
Analyst Count
10
6
Target Price
$15.39
$28.08
AVG Volume (30 Days)
2.1M
2.8M
Earning Date
05-25-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.79
EPS
N/A
N/A
Revenue
$2,723,400,000.00
$655,353,000.00
Revenue This Year
N/A
$7.72
Revenue Next Year
$2.96
$6.74
P/E Ratio
N/A
N/A
Revenue Growth
1.00
8.28
52 Week Low
$3.97
$9.82
52 Week High
$18.67
$21.55

Technical Indicators

Market Signals
Indicator
FTRE
NVCR
Relative Strength Index (RSI) 32.76 56.71
Support Level $9.35 $12.66
Resistance Level $11.41 $14.25
Average True Range (ATR) 1.01 1.19
MACD 0.08 0.30
Stochastic Oscillator 57.60 58.28

Price Performance

Historical Comparison
FTRE
NVCR

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Share on Social Networks: